Dopamine Metabolism in Human Brain: Effects of Monoamine Oxidase Inhibition in vitro by (—)Deprenyl and (+) and (—)Tranylcypromine

  • G. P. Reynolds
  • P. Riederer
  • W.-D. Rausch
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 16)


The effects of the monoamine oxidase inhibitors (-)deprenyl and (+)- and (-)tranylcypromine on dopamine oxidation in human caudate have been investigated. Oxidation of dopamine has been found to exhibit both (-)deprenyl-sensitive and -insensitive components. The tranylcypromine isomers are both more sensitive towards dopamine than 5-hydroxytrypt- amine oxidation, the (+) isomer being the more effective of the two. These results are discussed in terms of the in vivo action of the drugs and their therapeutic value.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer, W., Hornykiewicz, O.: Der L-3, 4-Dioxyphenylalanin- (= Dopa)-Effect bei der Parkinson-Akinese. Wien. klin. Wschr. 73, 787 (1961).PubMedGoogle Scholar
  2. Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W.: Potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B deprenil. J. Neural Transm. 36, 303–323 (1975).PubMedCrossRefGoogle Scholar
  3. Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M. B. H.: Implications of combined treatment with “Madopar” and deprenil in Parkinson’s disease: a long term study. Lancet I, 434–443 (1977).Google Scholar
  4. Eisworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lees, A. J., Phuapradit, P., Shaw, K. M., Stern, G. M., Kumar, P.: Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacol. 57, 33–38 (1978).CrossRefGoogle Scholar
  5. Fuentes, J. A., Oleshansky, M. A., Neff, N. H.: Comparison of the apparent antidepressant activity of (-) and (+) tranylcypromine in an animal model. Biochem. Pharmacol. 25, 801–804 (1976).PubMedCrossRefGoogle Scholar
  6. Glover, V., Sandler, M., Owen, F., Riley, G.J.: Dopamine is a monoamine oxidase B substrate in man. Nature 265, 80–81 (1977).PubMedCrossRefGoogle Scholar
  7. Lees, A.J., Shaw, K. M., Kohout, L. J., Stern, G. M., Eisworth, J. D., Sandler, M., Youdim, M. B. H.: Deprenyl in Parkinson’s disease. Lancet II, 791–796 (1977).CrossRefGoogle Scholar
  8. Neff, N. H., Fuentes, J. A.: The use of selective monoamine oxidase inhibitor drugs for evaluating pharmacological and physiological mechanisms. In: Monoamine oxidase and its inhibition (Wolstenholme, G.E.W., Knight, J., eds), pp. 163–173. Amsterdam: Elsevier. 1976.Google Scholar
  9. Reynolds, G. P., Riederer, P., Sandler, M., Jellinger, K., Seemann, D.: Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration. J. Neural Transm. 43, 271–277 (1978).PubMedCrossRefGoogle Scholar
  10. Reynolds, G. P., Rausch, W.-D., Riederer, P.: Effects of tranylcypromine stereoisomers on monoamine oxidation in man. Brit. J. Clin. Pharmacol. (1980, in press).Google Scholar
  11. Riederer, P., Reynolds, G. P., Birkmayer, W., Youdim, M. B. H., Jellinger, K.: (-)Deprenyl has a band of selectivity for therapeutic action. In: Proceedings of the 3rd Hungarian Pharmacological Congress, 1979.Google Scholar
  12. Suzuki, O., Katsumata, Y., Oya, M., Matsumoto, T.: Effect of β-phenylethylamine concentration on its substrate specificity for type A and type B monoamine oxidase. Biochem. Pharmacol. 28, 953–956 (1979).PubMedCrossRefGoogle Scholar
  13. Tipton, K., Youdim, M.B.H.: Assay of monoamine oxidase. In: Monoamine oxidase and its inhibition (Wolstenholme, G. E. W., Knight, J., eds.), pp. 393–403. Amsterdam: Elsevier. 1976.Google Scholar
  14. White, H., Tansik, R. L.: Characterisation of multiple substrate bin ding sites of MAO. In: Symposium on Monoamine oxidase structure, function and altered functions. Midland, Michigan, 1979.Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • G. P. Reynolds
    • 1
  • P. Riederer
    • 1
    • 2
  • W.-D. Rausch
    • 1
  1. 1.Neurochemistry Group, Ludwig Boltzmann-Institute of Clinical NeurobiologyLainz-HospitalWienAustria
  2. 2.Neurochemistry Group, Ludwig Boltzmann-Institute of Clinical NeurobiologyLainz-HospitalWienAustria

Personalised recommendations